Drug-resistant tuberculosis: Progress towards shorter and safer regimens.
作者信息
Saravu Kavitha, Pai Madhukar
机构信息
Department of Medicine, Kasturba Medical College, Manipal Academy of Higher Education; Manipal McGill Program for Infectious Diseases, Manipal Center for Infectious Diseases,Prasanna School of Public Health, Manipal Academy of Higher Education, Manipal, Karnataka, India.
Manipal McGill Program for Infectious Diseases, Manipal Center for Infectious Diseases, Prasanna School of Public Health, Manipal Academy of Higher Education, Manipal, Karnataka, India; McGill International Tuberculosis Centre, McGill University, Montreal, Canada.
出版信息
Lung India. 2019 Sep-Oct;36(5):373-375. doi: 10.4103/lungindia.lungindia_350_19.
Abstract
摘要
相似文献
1
Drug-resistant tuberculosis: Progress towards shorter and safer regimens.耐多药结核病：在实现更短、更安全治疗方案方面取得的进展。
Lung India. 2019 Sep-Oct;36(5):373-375. doi: 10.4103/lungindia.lungindia_350_19.
2
Towards shorter, safer, flexible, and more effective treatment regimens for drug-resistant tuberculosis.朝着更短、更安全、更灵活且更有效的耐多药结核病治疗方案发展。
Lancet Respir Med. 2024 Dec;12(12):939-941. doi: 10.1016/S2213-2600(24)00300-X. Epub 2024 Oct 1.
3
Tuberculosis: progress and advances in development of new drugs, treatment regimens, and host-directed therapies.结核病：新药、治疗方案和宿主导向治疗的开发进展和进展。
Lancet Infect Dis. 2018 Jul;18(7):e183-e198. doi: 10.1016/S1473-3099(18)30110-5. Epub 2018 Mar 23.
4
Cost comparison of nine-month treatment regimens with 20-month standardized care for the treatment of rifampicin-resistant/multi-drug resistant tuberculosis in Nigeria.尼日利亚利福平耐药/耐多药结核病 9 个月治疗方案与 20 个月标准化护理成本比较。
PLoS One. 2020 Dec 1;15(12):e0241065. doi: 10.1371/journal.pone.0241065. eCollection 2020.
5
[Not Available].[无可用内容]。
Presse Med. 2017 Mar;46(2 Pt 2):e41-e51. doi: 10.1016/j.lpm.2017.01.016. Epub 2017 Feb 28.
6
New Drugs and Regimens for Tuberculosis Disease Treatment in Children and Adolescents.儿童和青少年结核病治疗的新药和新方案。
J Pediatric Infect Dis Soc. 2022 Oct 31;11(Supplement_3):S101-S109. doi: 10.1093/jpids/piac047.
7
Progress in tuberculosis vaccine development and host-directed therapies--a state of the art review.结核病疫苗研发和宿主导向疗法的进展——最新综述。
Lancet Respir Med. 2014 Apr;2(4):301-20. doi: 10.1016/S2213-2600(14)70033-5. Epub 2014 Mar 24.
8
Standardised shorter regimens individualised longer regimens for rifampin- or multidrug-resistant tuberculosis.利福平耐药或耐多药结核病的标准化短程治疗方案与个体化长程治疗方案。
Eur Respir J. 2020 Mar 20;55(3). doi: 10.1183/13993003.01467-2019. Print 2020 Mar.
9
Multi and extensively drug-resistant pulmonary tuberculosis: advances in diagnosis and management.广泛耐药和耐多药肺结核：诊断与治疗的新进展。
Curr Opin Pulm Med. 2018 May;24(3):244-252. doi: 10.1097/MCP.0000000000000477.
引用本文的文献
1
Controlling the drug-resistant tuberculosis epidemic in India: challenges and implications.控制印度的耐药结核病疫情：挑战与影响。
Epidemiol Health. 2021;43:e2021022. doi: 10.4178/epih.e2021022. Epub 2021 Apr 7.
2
Detection of Second Line Drug Resistance among Drug Resistant Mycobacterium Tuberculosis Isolates in Botswana.博茨瓦纳耐药结核分枝杆菌分离株二线耐药性的检测
Pathogens. 2019 Oct 28;8(4):208. doi: 10.3390/pathogens8040208.
本文引用的文献
1
Treatment outcome of multidrug-resistant tuberculosis with modified DOTS-plus strategy: A 2 years' experience.采用改良强化间歇短程化疗策略治疗耐多药结核病的疗效：两年经验
Lung India. 2019 Sep-Oct;36(5):384-392. doi: 10.4103/lungindia.lungindia_475_18.
2
What will it take to eliminate drug-resistant tuberculosis?消除耐多药结核病需要什么？
Int J Tuberc Lung Dis. 2019 May 1;23(5):535-546. doi: 10.5588/ijtld.18.0217.
3
A Trial of a Shorter Regimen for Rifampin-Resistant Tuberculosis.一项针对耐利福平结核病的较短疗程的试验。
N Engl J Med. 2019 Mar 28;380(13):1201-1213. doi: 10.1056/NEJMoa1811867. Epub 2019 Mar 13.
4
Delamanid, linezolid, levofloxacin, and pyrazinamide for the treatment of patients with fluoroquinolone-sensitive multidrug-resistant tuberculosis (Treatment Shortening of MDR-TB Using Existing and New Drugs, MDR-END): study protocol for a phase II/III, multicenter, randomized, open-label clinical trial.地拉米胺、利奈唑胺、左氧氟沙星和吡嗪酰胺用于治疗氟喹诺酮敏感的耐多药结核病患者（使用现有和新药缩短耐多药结核病治疗时间，MDR-END）：一项II/III期、多中心、随机、开放标签临床试验的研究方案
Trials. 2019 Jan 16;20(1):57. doi: 10.1186/s13063-018-3053-1.
5
Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis.肺耐多药结核病成功治疗结果的相关因素：一项个体患者数据荟萃分析。
Lancet. 2018 Sep 8;392(10150):821-834. doi: 10.1016/S0140-6736(18)31644-1.
6
Short-course treatment for multidrug-resistant tuberculosis: the STREAM trials.耐多药结核病的短程治疗：STREAM试验
Eur Respir Rev. 2016 Mar;25(139):29-35. doi: 10.1183/16000617.0080-2015.
Zotero 插件